Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States.
The last earnings update was 54 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Synthetic Biologics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Synthetic Biologics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Synthetic Biologics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Synthetic Biologics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Synthetic Biologics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Synthetic Biologics's finances.
The net worth of a company is the difference between its assets and liabilities.
Synthetic Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Synthetic Biologics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Synthetic Biologics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Synthetic Biologics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Steven A. Shallcross, also known as Steve, CPA has been the Chief Financial Officer, Treasurer and Secretary at Synthetic Biologics, Inc. since joining in June 1, 2015 and also been its Chief Executive Officer since 2018. He had been an Interim Chief Executive Officer at Chief Executive Officer since December 5, 2017. Mr. Shallcross has been a Director of Synthetic Biologics, Inc. since December 6, 2018. He served as the Chief Financial Officer, Executive Vice President, Treasurer and Secretary of Nuo Therapeutics, Inc. (Cytomedix, Inc.) from May 10, 2013 to May 25, 2015. Mr. Shallcross served as the Chief Financial Officer of Innocoll AG (alternative name Innocoll, Inc.) January 2009 to March 2011. He served as Chief Financial Officer, Senior Vice President and Treasurer of Vanda Pharmaceuticals Inc. from November 2005 to January 9, 2009 and also served as its Principal Accounting Officer. He has over 20 years of senior financial and operations experience in emerging organizations, including acquisitions and restructurings. From October 2001 to November 2005, he served as the Senior Vice President and Chief Financial Officer of MiddleBrook Pharmaceuticals, Inc. (formerly, Advancis Pharmaceutical Corporation). Mr. Shallcross served as Treasurer of MiddleBrook from August 2003 to November 2005, Secretary since October 2001 and also served as its Principal Accounting Officer. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. Mr. Shallcross served as the Vice President of Finance and Chief Financial Officer of Bering Truck Corporation from August 1997 to 2001. From 1993 to 1997, he served as the Vice President of Operations at Precision Scientific, Inc. He served as a Controller of Precision Scientific from June 1993 to January 1994. He serves as the Chairman of the Financial Executive Forum for the Technology Council of Maryland, a board member of the Washington D.C. chapter of Financial Executives International and is a steering committee member for the Baltimore - Washington Area Association of Bioscience Financial Officers. He is a Certified Public Accountant. Mr. Shallcross received a Bachelor of Science degree degree in Accounting from the University of Illinois and an M.B.A. from the University of Chicago, Graduate School of Business.
Steve's compensation has increased whilst company is loss making.
Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Synthetic Biologics management team is about average.
Director of Corporate Communication
Head of Product and Corporate Development
Senior Vice President of Research & Development
Senior Vice President of Manufacturing
Senior Director of Project Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Synthetic Biologics board of directors is about average.
Board of Directors
Independent Non-Executive Chairman
Chairman of C-IBS Clinical Advisory Board
Chairman of C Difficile Clinical Advisory Board
Member of Infectious Disease Scientific Advisory Board
Member of C Difficile Clinical Advisory Board
Member of C Difficile Clinical Advisory Board
Member of C Difficile Clinical Advisory Board
Who owns this company?
Recent Insider Trading
Synthetic Biologics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.